Hip fractures increase exponentially beyond the seventh decade of life, as does the risk of their devastating consequences, which include functional decline, institutionalization, mortality, and destitution. Clinicians are often hesitant to start pharmacologic treatment in older adults, particularly those with multiple comorbidities, polypharmacy, and frailty. This reluctance stems in part from the concern that these patients with a shorter life expectancy may not experience the same risk-benefit profile as healthier adults when prescribed preventive therapies.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Berry SD, Shi S, Kiel DP. Considering the Risks and Benefits of Osteoporosis Treatment in Older Adults. JAMA Intern Med. 2019;179(8):1103–1104. doi:10.1001/jamainternmed.2019.0688
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: